Daniel Snyder, Head, Medical Affairs, REVANCE THERAPEUTICS

Brenna E. Jenny, Counsel, U.S. DEPARTMENT OF JUSTICE

Elizabeth Faust, Ph.D., Vice President, Medical Affairs, KITE PHARMA

Jayne Gershkowitz, Chief Patient Advocate, AMICUS THERAPEUTICS

Heather S. Ambrose, Director, Acute Care Field Medical and Patient Advocacy, BTG INTERNATIONAL

Christine Chatas, Director, Medical Liaisons, ALEXION PHARMACEUTICALS

Vaibhav Katkade, M.D., Ph.D., SeniorDirector, Global TA Medical Lead, Rheumatoid Arthritis Inflammation and Immunology Medical Affairs, PFIZER

Cristina Costantino, Ph.D., MBA, Senior Scientific Communications Director, GENENTECH

Christian Dimaano, Ph.D., MPH, National Director, Oncology MSLs, Medical Affairs, Americas, ASTELLAS PHARMA

Radhika Tripuraneni, M.D., Vice President, Medical Affairs, PROTHENA BIOSCIENCES

Julie Baron, Ph.D., Director, Field Medical Effectiveness, SHIRE

Susan Malecha, Pharm.D., MBA, Lead, National Managed Care Liaisons, PACE (Patient Access Collaboration and Exchange), U.S. Medical Affairs, GENENTECH

Duke Dickerson, Ph.D., M.Sc., MBA, Regional Medical Director, Orphan and Rare Diseases, HORIZON PHARMA

Julie Greely, Pharm.D., Senior Director, Field Excellence and HEOR, Medical Affairs, Americas, ASTELLAS PHARMA INC

Tricia L. Gooljarsingh, Senior Director, Medical and Scientific Affairs, IRONWOOD PHARMACEUTICALS

Colville Brown, M.D., Medical Director, EGALET CORPORATION

SPONSORS

MEDICAL AFFAIRS EXECUTIVE STRATEGY MSL BEST PRACTICES

OUR 2018 Expert Speakers Featuring Presentations,

Panel Discussions and CaseStudies, Including:

Two Tracks

September 24–26, 2018 | San Diego Marriott Del Mar | San Diego, CA

Develop a unified scientific voice and ultimately help position your medical affairs group as a strategic, customer-facing function

MEDICAL AFFAIRS STRATEGIC SUMMIT W

ES

T

Featuring Presentations, Panel Discussions and Case Studies, Including:

¨ DOJ Keynote Address: Enforcement Viewpoints and Priorities for the U.S. Department of Justice

¨ Medical Affairs Powering Up for an Effective Product Launch

¨ Appreciate the Evolution of the MSL and Pharma/Payer Trends That Offer Optimal Impactful Communication Tactics

¨ Panel: How to Set Up Compliance Firewalls That Balance SOPs With Practical Needs

¨ Panel: Develop a Streamlined Process for Gathering Clinical and Field Insights and Translate That Data Internally to Shape Medical Strategy

¨ Successfully Operationalizing a Franchise-Level Scientific Communication Platform

Dear Colleague,

Life science companies continue to generate more data than they know how to handle. Innovative tools and platforms can allow companies to dissect this information, identify trends, and highlight gaps in patient care that they can help bridge. Medical affairs professionals are perfectly positioned to be the gate-keepers of this data, responsible for identifying the evidence needs of a product, commissioning new data generating studies, and ensuring a product has the necessary scientific and clinical evidence to effectively communicate the value of a product to a broad group of stakeholders.

Home office and field medical professionals have deep product and scientific knowledge and are best positioned to be responsible for the market education and communication of a product's benefits ahead of a launch. The biggest challenge lies in streamlining communications and data sources across an organization to create unified, compliant messaging that is innovative and scientifically sound, while benefiting patients and a company's core customer base.

MASS West 2018 is an educational platform that provides a holistic view of medical affairs, allowing organizations to develop a unified scientific voice and help position themselves as a strategic and credible customer-facing partner in the healthcare marketplace. This event addresses the strategic and operational challenges facing medical affairs and field medical professionals and provides attendees with the opportunity to attend sessions from the following two tracks designed to improve the medical affairs and MSL function.

( Medical Affairs Executive Strategy

( MSL Best Practices

This unique learning format provides the opportunity for teams to choose their own adventure and tailor their educational experience to the needs of an organization. Don’t miss this opportunity to join the leading community of medical affairs professionals at MASS West 2018!

My team and I look forward to seeing you in San Diego!

Best regards,

Zohaib Sheikh Senior Conference Director

ExL Events, a division of Questex, LLC

✓ Medical Affairs/Field Medical Affairs✓ Clinical/Scientific Affairs✓ Medical Science Liaisons/MSLs✓ Medical Strategy/Communications✓ Medical/Clinical Operations✓ KOL/Thought Leader Relations/Engagement✓ Investigator-Initiated Research (IIR)✓ Investigator-Initiated Studies (IIS)✓ Investigator-Initiated Trials (IIT)✓ Investigator-Sponsored Trials (IST)✓ Research Collaborations✓ Medical/Scientific/Patient Communications✓ Medical Information✓ Medical Education✓ Publication Planning✓ Health Economics and Outcomes Research/HEOR✓ Compliance/Legal✓ Regulatory Affairs✓ Research Grants✓ Call Center Management✓ Patient Services✓ Clinical Outcomes and Publications

This conference is also designed for:

✓ KOL and Thought Leader Mapping Organizations✓ Data Management Vendors✓ Clinical Trial Service Providers✓ Scientific and Technology Solutions Providers✓ Medical Affairs Service Organizations✓ Medical and Scientific Communication Vendors✓ Talent Acquisition Service Providers✓ Call Center Vendors✓ Companion Diagnostics✓ Data Management Solution Providers

WHO SHOULD ATTEND This conference is designed for representatives from pharmaceutical, biotechnology, and medical device organizations with responsibilities in the following areas:

SAN DIEGO MARRIOTT DEL MAR 11966 El Camino Real San Diego, CA 92130

To make reservations, please call 877-759-6290 and request the negotiated rate for ExL's MASS West 2018. You may also make reservations online using the following weblink: https://bit.ly/2jDl1Rj. The group rate is available until September 4, 2018. Please book your room early, as rooms available at this rate are limited.

*ExL Events is not a affiliated with Exhibition Housing Management (EHM)/Exhibitors Housing Services (EHS) or any third-party booking agencies, bureaus or travel companies. ExL Events is affiliated with event company Questex, LLC. In the event that an outside party contacts you for any type of hotel or travel arrangements, please disregard these solicitations and kindly email us at info@exlevents.com. ExL has not authorized these companies to contact you and we do not verify the legitimacy of the services or rates offered. Please book your guest rooms through ExL’s reserved guest room block using the details provided.

SPONSORSHIP AND EXHIBITION OPPORTUNITIES Do you want to spread the word about your organization’s solutions and services to potential clients attending this event? Take advantage of the opportunity to exhibit, underwrite an educational session, host a networking event or distribute promotional items to attendees. ExL Events will work closely with you to customize a package that will suit all of your needs.

MONDAY, SEPTEMBER 24, 2018 PRECONFERENCE WORKSHOPS

8:00 Continental Breakfast

9:15 WORKSHOP A: Medical Affairs Powering Up for an Effective Product LaunchMedical Affairs plays a critical role in preparing the market for the successful launch of a product and can do so significantly and compliantly in advance of formal approval of the product by the regulatory authorities. A strong, collaborative partnership with their commercial, research and development teams can drive a strategically aligned launch plan that is high in scientific impact, and that helps to establish the product’s place in the treatment paradigm.This workshop will cover the essential components of a successful product launch including:

g Scientific Exchange Plan for engaging and managing thought leaders g Scientific Communication Platform that ensures effective and consistent dissemination of information

g Insight collection and analysis plan to litmus check the strategy for continued relevance g Robust publication, congress, medical information and continuing medical education plan

Tricia L. Gooljarsingh, Senior Director, Medical and Scientific Affairs, IRONWOOD PHARMACEUTICALS Cristina Costantino, Ph.D., MBA, Senior Scientific Communications Director, GENENTECH*This sessions contains a 30-minute networking break

WORKSHOP B: The Role of Medical Affairs and MSLs in Managing the Life Cycle of an IITInvestigator-initiated trials (IITs) play a vital role in the discovery of new drug indications and have opened the doors to achieving promising clinical outcomes and generating evidence that can be valuable for key external stakeholder communications. With life science organizations receiving an increasing number of IIT requests, medical affairs teams need to effectively evaluate whether an IIT proposal aligns with a company’s strategic priorities and overall medical strategy while gaining cross-functional buy-in. This workshop will explore the role of medical affairs and MSLs across the lifecycle of an IIT, and highlight how to optimize the review process, provide proper oversight after approval, and ensure the timely and successful execution of an IIT.

g Delve into how to manage goals and expectations when working with investigator-initiated trials and strategically gain cross-functional support for a growing IIT portfolio

g Determine ways to ensure quality outcomes through the understanding of feasibility, goals and resources

g Review financial, logistical and regulatory/legal aspects regarding supporting IITs  g Explore key tactics for MSLs and home office professionals to collaborate and effectively manage IITs

Kay Baldwin, Associate Regional Director, KERYX BIOPHARMACEUTICALS

Workshop A Concludes Workshop B Concludes12:15 Luncheon

1:30 WORKSHOP C: Rules of Engagement for MSLs – Appropriate Interactions With Internal and External StakeholdersThe MSL role establishes relationships with influential medical thought leaders to foster education and research of therapeutic agents, and to ultimately improve patient care practices.  This unique role involves frequent interactions between the pharmaceutical industry and the medical community where cutting-edge science and research are discussed.  This session will review the legal guidance (e.g., Food & Drug Administration {FDA}, Office of Inspector General {OIG}, Federal Anti-Kickback Statute {AKA}, Food, Drug and Cosmetic Act {FDCA}, and recent enforcements around Commercial and Medical Affairs interactions) that help define the legal and compliance “Rules of Engagement” by which MSLs function today.

g Consider how we got to the current “Rules of Engagement” and where the guidance comes from

g Discuss when to utilize an MSL g Understand how to respond to unsolicited requests g Explore compliant approaches to working with commercial, sales, reimbursement and managed market teams

Daniel Snyder, Head, Medical Affairs, REVANCE THERAPEUTICS*This sessions contains a 30-minute networking break

WORKSHOP D: Appreciate the Evolution of the MSL and Pharma/Payer Trends That Offer Optimal Impactful Communication TacticsUnprecedented changes in the healthcare landscape is forcing a broader role for Medical Science Liaisons. We’ll learn about the trend toward increasing the relevance of MSLs in supporting complex products in a complex marketplace and highlight how to optimize pharma/payer communications by understanding key trends:

g Understand development costs and physician, patient and clinical decision-making when approaching the marketplace (including precision medicine)

g Examine the rising cost of specialty products due to innovation, aging and expanding marketplaces and societal decision-making

g Discuss innovative strategies that can analyze and predict patient behavior and improve outcomes g Leverage technology to tailor engagement, assess patient adherence and drive better outcomes

Susan Malecha, Pharm.D., MBA, Lead, National Managed Care Liaisons, PACE (Patient Access Collaboration and Exchange), U.S. Medical Affairs, GENENTECH

*This sessions contains a 30-minute networking break

4:30 Workshop C Concludes Workshop D Concludes

7:30 Main Conference Registration and Continental Breakfast

8:30 Chairperson’s Opening Remarks

8:45 Keynote: Enforcement Viewpoints and Priorities for the U.S. Department of Justice• Understand the principles that govern the Department of Justice’s enforcement decisions• Examine current areas of enforcement priority for the Department of Justice under the Food, Drug, and Cosmetic Act and the False Claims Act• Learn about the implications for life sciences companies of the “Brand Memo,” which addresses the use of guidance documents in affirmative civil enforcement cases,

and the “Granston Memo,” which addresses government-initiated dismissals of False Claims Act qui tam suitsBrenna E. Jenny, Counsel, U.S. DEPARTMENT OF JUSTICE

9:30 Panel: Explore Different Operating Models for Medical Affairs Groups and Discuss How Organizational Structure Can Impact the Effectiveness of Your Activities

• Review some traditional and innovative operating models for medical affairs across big pharmaceutical and biotech companies• Highlight different groups and areas of focus that can be impacted based on the reporting and budgetary structure for a medical affairs group• Discuss the difference between expectations and challenges faced by medical and cross-functional leadership and how that can affect a team’s ability to do their job well

Radhika Tripuraneni, M.D., MPH, Vice President, Medical Affairs, PROTHENA BIOSCIENCES

10:15 Leveraging Online Discussion Platforms for Optimal Stakeholder Engagement• Identify the logistical and resource barriers to domestic and global stakeholder engagement• Learn about innovative communication solutions that leading organizations utilize to overcome these challenges• Discuss how to use these solutions to deliver improved engagement outcomes while maintaining regulatory compliance

Lance Hill, CEO, WITHIN3

10:45 Networking Break

TUESDAY, SEPTEMBER 25, 2018 MAIN CONFERENCE, DAY ONE

MEDICAL AFFAIRS EXECUTIVE STRATEGY MSL BEST PRACTICES

11:30 Track Chair Opening Remarks Track Chair Opening Remarks

11:45 How to Survive an Acquisition — A Medical Affairs Perspective g Review the different kinds of scenarios that require you to partner with another organization

g Analyze the impact of this arrangement on the development and execution of medical activities

g Determine what sort of arrangement best serves your business needs g Hear case examples and shared learnings from real-world scenarios from experiences

Elizabeth Faust, Ph.D., Vice President, Medical Affairs, KITE PHARMA

Create and Implement On-Boarding and Training Processes in Biotech/Pharmaceutical Medical Affairs Departments

g Collaborate with leadership across medical affairs (U.S. and Global) to understand current processes and/or existing resources

g Develop an on-boarding agenda to ensure critical start-up skills are completed and cross-collaborative relationships are initiated

g Incorporate training objectives in medical affairs goals/performance expectations to create a pool of peers across medical affairs that participate and lead training units

g Assign mentors with clear outlined responsibilities g Create processes to provide evidence that initial training is complete and knowledge has been assessed

Christine Chatas, Director, Medical Liaisons, ALEXION PHARMACEUTICALS12:30 Luncheon

1:30 Give the Patient Voice a Seat at the Table g Examine concerns patients have expressed regarding historical drug development processes

g Explain Amicus Therapeutics’ mission and achievements in becoming recognized as a patient-focused company

g Share real-world examples of ways patients and patient advocacy organizations have shaped Amicus’ novel drug development and commercialization programs

g Learn how best to become a patient-centric companyMark Lyles, M.D., MBA, Executive Director, Medical Affairs Strategy, AMICUS THERAPEUTICS Jayne Gershkowitz, Chief Patient Advocate, AMICUS THERAPEUTICS

Compliant Interactions Between Medical Affairs and Commercial Colleagues

g Understand how medical affairs and commercial can collaborate with respect to broad company and product strategies, while maintaining independence and scientific/medical integrity when exercising professional judgment and making decisions

g Develop actions and behaviors to help ensure compliance with related company policies, external laws and regulations, and industry standards and guidelines

g Learn how medical affairs work in alignment with commercial personnel to provide non-promotional, scientific and medical support to other cross-functional teams within an organization

Ayman R. Kafal, Ph.D., MBA, Associate Director, Specialty Field Team, Medical Affairs, CSL BEHRING

2:15 Take a Patient-Centric Approach to Medical Affairs Engagement g Improve outreach with detailed, multifaceted profiling that quickly identifies the right influencers and patient populations for your medical engagement.

g Optimize scientific engagements with real-time, online predictive data as well as offline analytics support to radically improved results at significantly greater speed.

g Deliver field-level intelligence on competitor engagements to help you prioritize and compliantly improve the impact of outreach efforts

Richard Kho, Ph.D., Head of Life Sciences and Customer Success, KOMODO HEALTH

Stakeholder Interests in Value Discussions Drive the Need for Better Field Medical Coordination

g Understand how the value discussion has evolved over time as a requirement by external stakeholders and learn the impact that both clinical and economic information can have for KOLs, payers, and healthcare systems

g Identify the most impactful outcomes data and resources used by value-based health decision makers to make informed decisions

g Discuss the different models that Field Medical Organizations leverage to address the value discussion externally and the value of coordinating field efforts between MSLs and Field HEOR/Managed Care Liaisons  

Christian Dimaano, Ph.D., MPH, National Director, Oncology MSLs, Medical Affairs, Americas, ASTELLAS PHARMA INCJulie Greely, Pharm.D., Senior Director, Field Excellence and HEOR, Medical Affairs, Americas, ASTELLAS PHARMA INC

3:00 Panel: How to Set Up Compliance Firewalls That Balance SOPs With Practical Needs

g Review the history of events that have lead companies to develop the compliance framework they have today

g Understand the origins, what has guided this framework and gain an overview of the legal perspective

g Learn how to work collaboratively, semi-autonomously or purely independently of other departments based on the culture at your organization

Daniel Snyder, Head, Medical Affairs, REVANCE THERAPEUTICS

How to Establish Your Medical Organization Prior to a Commercial Launch g Identify key leverage points to ensure successful market access g Establish and prepare your field medical team strategically g Put in place the right measures to demonstrate value and deliver on the promise

Julie Baron, Ph.D., Director, Field Medical Effectiveness, SHIRE

3:45 Networking Break4:15 Effective Use of Mobile Microlearning for Point-of-Need Training: How

One Fortune 50 BioPharma is Applying Technology for Increased Clinical Competency

g Determine how the cloud can precipitate more knowledgeable KOL interactions g Hear what happens when clinical data meets Google on YouTube g Learn how medical affairs/clinical operations teams can move towards continuous learning

Michael W. Young, Chief Marketing Officer, SCIENCEMEDIA, INC.Philip Bedrin, Director of Sales, North America, SCIENCEMEDIA, INC.

Maximize the Value of a Product Nearing the End of Its Patent Through Lifecycle Management

g Discuss how to keep generating science throughout a product's life cycle g Sustain thought leader relationships beyond the life cycle g Examine steps to retain market interest and engagement as patent expiration approaches

Sheila Komara, Ph.Dc., RN, Senior Medical Science Liaison, MALLINCKRODT PHARMACEUTICALS

5:00 Cocktail Reception

6:00 Day One Concludes

MEDICAL AFFAIRS EXECUTIVE STRATEGY MSL BEST PRACTICES

TUESDAY, SEPTEMBER 25, 2018 TRACKED SESSIONS BEGIN

MEDICAL AFFAIRS EXECUTIVE STRATEGY MSL BEST PRACTICES

8:00 Continental Breakfast

8:45 Track Chair Recap of Day One Track Chair Recap of Day One

9:00 Successfully Operationalizing a Franchise-Level Scientific Communication Platform

g Develop a franchise-level scientific communication platform (SCP) to achieve broad alignment on external communications supporting products, leverage strengths and opportunities, and optimize differentiation in a competitive landscape

g Create a tool for its dissemination for use by a cross-functional team and gain alignment on highest-priority goals for scientific communications, including scientific pillars and key stakeholders

g Discuss the benefits of an interactive tool that provides easy access to key information including franchise objectives, key communication points, and recommended counterpoints

g Identify outstanding data needs that may drive future research directions to support communication goals and broader commercial goals

Tricia L. Gooljarsingh, Senior Director, Medical and Scientific Affairs, IRONWOOD PHARMACEUTICALS

Use Data Mining Techniques to Enhance Customer Engagement g Explore different avenues and technologies that can allow MSL teams to profile and segment customer channels to support customer engagement

g Leverage external databases to identify discrepancies across therapeutic areas and extrapolate data for medical affairs needs

g Use these insights to develop enhanced resources for MSLs to engage their customer base

If you are interested in leading this session, please contact Michael Williams at mwilliams@exlevents.com.

9:45 Harness the Power of Technology and Data to Take Medical Affairs to the Next Level

g Consider how medical affairs is the hub of today's quality- and patient-centric healthcare system, responsible for educating and communicating with all healthcare stakeholders

g Personalize education and communications to recipient ‘s needs, preferences, and biases, in order to be most effective at changing behavior

g Take an interactive look at the impact of personalization on quality healthcareKatie Anders, Head of Medical Affairs Strategic Solutions (MASS), MEDSCAPE EDUCATION

Panel: Develop a Streamlined Process for Gathering Clinical and Field Insights and Translate That Data Internally to Shape Medical Strategy

g Discuss some of the challenges of leveraging CRMs to extract field insights in an intuitive manner

g Review the different types of intelligence collected g Develop a process to collect field intelligence, tier it based on importance/urgency, and report it up the management chain accordingly

g Use this process as a metric that tracks the frequency and quality of the feedback reported by team members

Vaibhav Katkade, M.D., Ph.D., Senior Director, Global TA Medical Lead, Rheumatoid Arthritis Inflammation and Immunology Medical Affairs, PFIZERCristina Costantino, Ph.D., MBA, Senior Scientific Communications Director, GENENTECHLynn Bass, Director, Medical Science Liaisons (Americas), SANTEN

10:30 Networking Break

11:00 Pharmacoeconomic Data That Can Impact Patients — Explore the Potential of Further Uses of Big Data

g Understand how RWD is essentially everything not in clinical trials and review the various sources for what is credible and informative

g Discuss how RWD can be beneficial for certain audiences, such as pharmaeconomic data for payers and patient profiles for clinicians, and how this data can be communicated to have lasting impact

g Discover how medical is responsible for taking a product to the next level after approval and how they can impact the patient further

Vaibhav Katkade, M.D., Ph.D., Senior Director, Global TA Medical Lead, Rheumatoid Arthritis Inflammation and Immunology Medical Affairs, PFIZER

Cost-Effective Tactics for Bringing Awareness and Medical Education to a Specific Disease State

g Identify well published and influential healthcare professionals that would be interested in training the next generation of KOLs/thought leaders

g Establish common goals and processes for these seasoned veterans to mentor these young physicians

g Consider the benefits of publishing open access papers onlineDuke Dickerson, Ph.D., M.Sc., MBA, Regional Medical Director, Orphan and Rare Diseases, HORIZON PHARMA

11:45 Luncheon12:45 When Will This Be Published? — Develop an Effective Medical

Communications Strategy to Ensure Timely Dissemination of Disease Background and Drug Product Information

g Draft a compelling publication plan in a dynamic environment g Optimize journal selection to reduce time from publication development to publishing g Utilize social media to improve the depth and breadth of target audience reach

Colville Brown, M.D., Medical Director, EGALET CORPORATION

Medical Affairs and Patient Advocacy – Where Do They Meet? g Gain an overview of the overall global strategy to roll out patient-centric programs g Identify opportunities to partner with patient advocacy groups and determine who is the best partner for your company

g Leverage these partnerships to understand what is best for the patient and don’t miss the opportunity to measure endpoints and outcomes important to key external stakeholders

g Work with compliance partners to create innovative patient-centric programs g Measure the performance and success of patient centricity

Heather S. Ambrose, Director, Acute Care Field Medical and Patient Advocacy, BTG INTERNATIONAL

1:30 Understand the Purpose of an Investigator-Initiated Trial From the Company Perspective

g Hear some of the strategic reasons why companies can benefit for investigator-initiated research

g Understand common pitfalls and challenges when managing IITs g Discover best practices for optimizing the life cycle of an IIT

Bruce M. Schechter, Pharm.D., CMPP, Director, Scientific Communications, Rheumatology Therapeutic Area Lead, Medical Scientific Affairs Operations,IRONWOOD PHARMACEUTICALS

Weigh the Benefits of Establishing an MSL Rotational Program g Highlight some of the obstacles field medical faces in gaining experience and exposure within the organization

g Identify opportunities and establish a framework for a MSL rotational program with buy-in from executive leadership

g Gain an overview of the rotational program and discuss key insightsKunal Ramani, Pharm.D., Senior Medical Science Liaison, STRONGBRIDGE BIOPHARMA

2:45 Track Chair Closing Remarks Track Chair Closing Remarks

3:00 Conference Concludes

MEDICAL AFFAIRS EXECUTIVE STRATEGY MSL BEST PRACTICES

WEDNESDAY, SEPTEMBER 26, 2018 TRACKED SESSIONS DAY TWO

MEDIA PARTNERS

Pricing to Attend ExL’s MASS West 2018

STANDARD Register After August 10, 2018 ONSITE

Conference + 2 Workshops $2,695 $2,795

Conference + 1 Workshop $2,395 $2,495

Conference Only $2,095 $2,195

WAYS TO REGISTER +1 201-871-0474 Click Here@ register@pmaconference.com

PMA Conference ManagementPOB 2303Falls ChurchVA 22042

253-663-7224

Save 15% Can only send three? You can still save 15% off of each registration.

To find out more on how you can take advantage of these group discounts, please call 201-871-0474.

Save 25% For every three simultaneous registrations from your company, you will receive a fourth complimentary registration to the program (must register four at one time).

TERMS AND CONDITIONS: By registering for an ExL Events (“ExL”) event, you agree to the following set of terms and conditions listed below:

REGISTRATION FEE: The fee includes the conference‚ all program materials‚ and designat-ed continental breakfasts‚ lunches and refreshments.

PAYMENT: Make checks payable to ExL Events and write 700518 on your check. You may also use Visa, MasterCard, Discover or American Express. Payments must be received in full by the conference date. Any discount applied cannot be combined with any other offer and must be paid in full at the time of order. Parties must be employed by the same organization and register simultaneously to realize group discount pricing options.

**Please Note: There will be an administrative charge of $300 to substitute, exchange and/or replace attendance badges with a colleague within five business days of any ExL conference.**

CANCELLATION AND REFUND POLICY: If you cancel your registration for an upcoming ExL event, the following policies apply, derived from the Start Date of the event:• Four weeks or more: A full refund (minus a $295 processing fee) or a voucher to anoth-

er ExL event valid for 12 months from the voucher issue date.• Less than four weeks: A voucher to another ExL event valid for 12 months from the

voucher issue date.• Five days or less: A voucher (minus a $395 processing and documentation fee) to

another ExL event valid for 12 months from the voucher issue date.

To receive a refund or voucher, please email cancel@exlevents.com or fax your request

CREDIT VOUCHERS: Credit vouchers are valid for 12 months from date of issue. Credit vouchers are valid toward one (1) ExL event of equal or lesser value. If the full amount of said voucher is not used at time of registration, any remaining balance is not applica-ble now or in the future. Once a credit voucher has been applied toward a future event, changes cannot be made. In the event of cancellation on the attendees’ behalf, the credit voucher will no longer be valid.

ExL Events does not and is not obligated to provide a credit voucher to registered attend-ee(s) who do not attend the event they registered for unless written notice of intent to cancel is received and confirmed prior to the commencement of the event.

SUBSTITUTION CHARGES: There will be an administrative charge of $300 to substitute, exchange and/or replace attendee badges with a colleague occurring within five business days of the conference.

ExL Events reserves the right to cancel any conference it deems necessary and will not be responsible for airfare‚ hotel or any other expenses incurred by registrants.

ExL Events’ liability is limited to the conference registration fee in the event of a cancella-tion and does not include changes in program date‚ content‚ speakers and/or venue.

*The opinions of ExL’s conference speakers do not necessarily reflect those of the compa-nies they represent, nor ExL Events.

Please Note: Speakers and agenda are subject to change without notice. In the event of a speaker cancellation, significant effort to find a suitable replacement will be made. The content in ExL slide presentations, including news, data, advertisements and other information, is provided by ExL’s designated speakers and is designed for informational purposes for its attendees. It is NOT INTENDED for purposes of copywriting or redis-tribution to other outlets without the express written permission of ExL’s designated speaking parties. Neither ExL nor its content providers and/or speakers and attendees shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. EXL EVENTS EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESSED OR IMPLIED, AS TO THE ACCURACY OF ANY CONTENT PROVIDED, OR AS TO THE FITNESS OF THE INFORMATION FOR ANY PURPOSE. Although ExL makes reasonable efforts to obtain reliable content from third parties, ExL does not guarantee the accuracy of, or endorse the views or opinions given by any third-party content provider. ExL presentations may point to other websites that may be of interest to you, however ExL does not endorse or take responsibility for the content on such other sites.

GROUP DISCOUNT PROGRAMS *OFFERS MAY NOT BE COMBINED, EARLY BIRD RATES DO NOT APPLY*